In a filing, Crinetics Pharmaceuticals Inc revealed its Chief Med and Dev Officer Pizzuti Dana unloaded Company’s shares for reported $0.2 million on Feb 03 ’25. In the deal valued at $39.07 per share,5,000 shares were sold. As a result of this transaction, Pizzuti Dana now holds 31,748 shares worth roughly $1.11 million.
Then, DANA J PIZZUTI bought 5,000 shares, generating $195,372 in total proceeds.
Before that, Pizzuti Dana sold 15,000 shares. Crinetics Pharmaceuticals Inc shares valued at $781,350 were divested by the Chief Med and Dev Officer at a price of $52.09 per share. As a result of the transaction, Pizzuti Dana now holds 29,248 shares, worth roughly $1.02 million.
TD Cowen initiated its Crinetics Pharmaceuticals Inc [CRNX] rating to a Buy in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in early February with a ‘”a Peer perform”‘ rating. Jefferies also remained covering CRNX and has increased its forecast on January 22, 2025 with a “Buy” recommendation from previously “Hold” rating. Citigroup started covering the stock on March 06, 2024. It rated CRNX as “a Buy”.
Price Performance Review of CRNX
On Tuesday, Crinetics Pharmaceuticals Inc [NASDAQ:CRNX] saw its stock fall -4.38% to $34.93. Over the last five days, the stock has lost -13.54%. Crinetics Pharmaceuticals Inc shares have fallen nearly -31.68% since the year began. Nevertheless, the stocks have fallen -9.17% over the past one year. While a 52-week high of $62.53 was reached on 01/03/25, a 52-week low of $35.51 was recorded on 02/11/25. SMA at 50 days reached $47.32, while 200 days put it at $50.36.
Levels Of Support And Resistance For CRNX Stock
The 24-hour chart illustrates a support level at 34.01, which if violated will result in even more drops to 33.09. On the upside, there is a resistance level at 36.26. A further resistance level may holdings at 37.58. The Relative Strength Index (RSI) on the 14-day chart is 28.81, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.42, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.26%. Stochastics %K at 4.95% indicates the stock is a buying.
How much short interest is there in Crinetics Pharmaceuticals Inc?
A steep rise in short interest was recorded in Crinetics Pharmaceuticals Inc stocks on 2025-01-31, growing by 0.46 million shares to a total of 7.38 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-31 was 6.92 million shares. There was a rise of 6.24%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 16, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $50 price target.
